Global animal health company Zoetis has told the lead applicants in a class action over horse vaccines to “put up or shut up” and produce evidence disclosing an alleged scientific link between the hendra virus vaccine and certain alleged adverse side effects.
The lead applicants in a class action against The Cosmetic Institute have added 11 cosmetic surgeons to the lawsuit, alleging they conducted breast augmentation surgery in an “incompetent” manner.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
A judge has adjourned an interlocutory application because of deficient pleadings in a class action brought against three medical device manufacturers and a former doctor on behalf of thousands of women who claim to have suffered lifelong complications from pelvic mesh implants.
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
The company that operates the Newmarch House nursing home in Sydney is facing a possible class action after a coronavirus outbreak at the facility resulted in the deaths of 19 residents.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract “incorporeal” genetic information that is naturally found within the DNA of an unborn foetus.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.
In a defeat to the Australian Securities and Investments Commission, a judge has found a key witness in the trial against former Quintis director Frank Wilson must give evidence in person, delaying the hearing indefinitely until coronavirus-related travel restrictions are lifted.